Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing.

Expert review of cardiovascular therapy - 1 Mar 2010

Grant Richard W, Wexler Deborah J

Abstract excerpt

Continuing advances in genetic discovery have uncovered several dozen loci that are associated with Type 2 diabetes, including genetic variants that appear to modify responses to commonly prescribed diabetes medications. The use of an individual's genetic information to guide therapy choices raises the possibility of 'personalized medicine', wherein each patient's treatment plan is tailored based on genotype...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Blood Glucose
Share to Confidence Intervals

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Cytochrome P-450 Enzyme System

Share to Probability

Share to Proportional Hazards Models

Share to Sulfonylurea Compounds

Source

Open in PubMed Open full text

Identifiers

PMID: 20222813
DOI: 10.1586/erc.10.5
PMCID: PMC2852129

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss-of-function CYP2C9 variants: finding the correct clinical role for Type 2 diabetes pharmacogenetic testing.PMID 20222813Read ↗

Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.Semantic proximity Read ↗

Pharmacogenetics and personalized treatment of type 2 diabetesSemantic proximity Read ↗

Implications of Genetic Elements on Type 2 Diabetes Mellitus Pathogenesis and Management.Semantic proximity Read ↗

Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphismsSemantic proximity Read ↗

Pharmacogenetics in type 2 diabetes: precision medicine or discovery tool?Semantic proximity Read ↗

The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs.Semantic proximity Read ↗

Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?Semantic proximity Read ↗

CYP2C19 Loss‐of‐function Polymorphisms are Associated with Reduced Risk of Sulfonylurea Treatment Failure in Chinese Patients with Type 2 DiabetesSemantic proximity Read ↗

Pharmacogenetics and target identification in diabetes.Semantic proximity Read ↗

Association Between the CYP2C9 Genotype and Hypoglycemia Among Patients With Type 2 Diabetes Receiving Sulfonylurea Treatment: A Meta-analysis.Semantic proximity Read ↗

Pharmacogenetics for type 2 diabetes: practical considerations for study design.Semantic proximity Read ↗

Genetic and Clinical Predictive Factors of Sulfonylurea Failure in Patients with Type 2 Diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.